I-Flow Corp.
This article was originally published in The Gray Sheet
Executive Summary
Inks agreement with SoloPak Pharmaceuticals to distribute SideKick and Paragon ambulatory infusion systems and related disposables and accessories in the U.S. through Dec. 31, 1997. "The agreement provides for minimum purchase quotas for 1994, 1995 and the first half of 1996 which aggregate $16.9 mil.," I-Flow says in a release. Beginning July 1, 1996, SoloPak may purchase U.S. rights to the products for $8 mil. "If SoloPak does not exercise its option, the minimum purchases for the second half of 1996 and for 1997 will be substantially higher than those in the earlier period of the agreement," the firm notes
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.